Claudio Iovino1, Enrico Peiretti2, Filippo Tatti2, Giuseppe Querques3, Enrico Borrelli3, Riccardo Sacconi3, Jay Chhablani4, Hitesh Agrawal5, Camiel J F Boon6,7, Elon H C van Dijk6, Gilda Cennamo8, Marco Lupidi9, Alessio Muzi9, Valentina Di Iorio1, Matias Iglicki10, Lital Smadar11, Anat Loewenstein11, Dinah Zur12. 1. Eye Clinic, Multidisciplinary Department of Medical, Surgical and Dental Sciences, University of Campania Luigi Vanvitelli, Naples, Italy. 2. Department of Surgical Sciences, Eye Clinic, University of Cagliari, Cagliari, Italy. 3. Ophthalmology Department, San Raffaele University Hospital, Milan, Italy. 4. UPMC Eye Center, University of Pittsburgh, Pittsburgh, PA, USA. 5. LV Prasad Eye Institute, Hyderabad, India. 6. Department of Ophthalmology, Leiden University Medical Center, Leiden, The Netherlands. 7. Department of Ophthalmology, Amsterdam University Medical Centers, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. 8. Eye Clinic, Public Health Department, University of Naples Federico II, Naples, Italy. 9. Department of Surgical and Biomedical Sciences, Section of Ophthalmology, University of Perugia, S. Maria della Misericordia Hospital, Perugia, Italy. 10. Private Retina Practice, University of Buenos Aires, Buenos Aires, Argentina. 11. Division of Ophthalmology, Tel Aviv Sourasky Medical Center affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 12. Division of Ophthalmology, Tel Aviv Sourasky Medical Center affiliated to Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. dinahzur@gmail.com.
Abstract
BACKGROUND: To investigate the anatomical and functional results in eyes with peripapillary pachychoroid syndrome (PPS) undergoing photodynamic therapy (PDT). METHODS: A total of 25 eyes from 23 patients with PPS treated with PDT were retrospectively evaluated in this multicentric study. Main outcome measure was the proportion of eyes that achieved treatment success, defined as a decrease in both subretinal fluid (SRF) height and central subfield thickness (CST), at 3 months after PDT compared to baseline. Secondary outcomes were the change in CST, SRF, and best-corrected visual acuity (BCVA) 3 months after treatment and predictive factors for treatment success. When available, data between 3 and 12 months were also reviewed. RESULTS: Treatment success was achieved in 16 eyes (64%). In the total cohort, CST decreased significantly from 356 ± 118 µm at baseline to 282 ± 90 µm and 270 ± 91 µm at 1 and 3 months, respectively (p < 0.001). Maximal SRF height decreased significantly from 102 ± 83 µm at baseline to 38 ± 46 µm and 32 ± 42 µm at 1 and 3 months, respectively (p < 0.001), and remained stable at month 6 (29 ± 44 µm) and month 12 (23 ± 35 µm). BCVA improved significantly from baseline to month 3 (p = 0.021). CONCLUSIONS: PDT can be considered an efficacious treatment option in patients with PPS. Prospective data with longer follow-up in a bigger cohort are needed in order to determine the optimal treatment algorithm in this relatively novel disease.
BACKGROUND: To investigate the anatomical and functional results in eyes with peripapillary pachychoroid syndrome (PPS) undergoing photodynamic therapy (PDT). METHODS: A total of 25 eyes from 23 patients with PPS treated with PDT were retrospectively evaluated in this multicentric study. Main outcome measure was the proportion of eyes that achieved treatment success, defined as a decrease in both subretinal fluid (SRF) height and central subfield thickness (CST), at 3 months after PDT compared to baseline. Secondary outcomes were the change in CST, SRF, and best-corrected visual acuity (BCVA) 3 months after treatment and predictive factors for treatment success. When available, data between 3 and 12 months were also reviewed. RESULTS: Treatment success was achieved in 16 eyes (64%). In the total cohort, CST decreased significantly from 356 ± 118 µm at baseline to 282 ± 90 µm and 270 ± 91 µm at 1 and 3 months, respectively (p < 0.001). Maximal SRF height decreased significantly from 102 ± 83 µm at baseline to 38 ± 46 µm and 32 ± 42 µm at 1 and 3 months, respectively (p < 0.001), and remained stable at month 6 (29 ± 44 µm) and month 12 (23 ± 35 µm). BCVA improved significantly from baseline to month 3 (p = 0.021). CONCLUSIONS: PDT can be considered an efficacious treatment option in patients with PPS. Prospective data with longer follow-up in a bigger cohort are needed in order to determine the optimal treatment algorithm in this relatively novel disease.
Authors: Roy H Loo; Ingrid U Scott; Harry W Flynn; J Donald M Gass; Timothy G Murray; Mary Lou Lewis; Phillip J Rosenfeld; William E Smiddy Journal: Retina Date: 2002-02 Impact factor: 4.256
Authors: Thomas J van Rijssen; Elon H C van Dijk; Suzanne Yzer; Kyoko Ohno-Matsui; Jan E E Keunen; Reinier O Schlingemann; Sobha Sivaprasad; Giuseppe Querques; Susan M Downes; Sascha Fauser; Carel B Hoyng; Felice Cardillo Piccolino; Jay K Chhablani; Timothy Y Y Lai; Andrew J Lotery; Michael Larsen; Frank G Holz; K Bailey Freund; Lawrence A Yannuzzi; Camiel J F Boon Journal: Prog Retin Eye Res Date: 2019-07-15 Impact factor: 21.198
Authors: Nopasak Phasukkijwatana; K Bailey Freund; Rosa Dolz-Marco; Mayss Al-Sheikh; Pearse A Keane; Catherine A Egan; Sandeep Randhawa; Jay M Stewart; Qingyun Liu; Alex P Hunyor; Allan Kreiger; Aaron Nagiel; Robert Lalane; Mansour Rahimi; Won Ki Lee; Lee M Jampol; David Sarraf Journal: Retina Date: 2018-09 Impact factor: 4.256